Compare Royalty Pharma plc Class A Ordinary Shares (RPRX) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royalty Pharma plc Class A Ordinary Shares vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.27 (market cap $2.28B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 11.1× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| RPRX | SLS | |
|---|---|---|
Market Cap | $25.27B | $2.28B |
Volume | 3,671,183 | 3,128,960 |
Sector | Health | Health |
52-Week High | $63.96 | $15.46 |
52-Week Low | $35.44 | $1.39 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $32.50B | $2.15B |
Dividend Yield | 1.66% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
